Entering text into the input field will update the search result below

NanoViricides reports positive early-stage data on broad-spectrum drug candidate; shares up 45% premarket

  • NanoViricides' (NYSE:NNVC) has successfully completed the first safety/toxicology studies evaluating broad-spectrum drug candidate NV-HHV-101, a topical cream formulation, in mini-pigs.  All dose levels were well-tolerated with no safety signals observed.
  • Shingles rash will be the first targeted indication for the product.
  • Shares are up 45% premarket.

Recommended For You

More Trending News

About NNVC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NNVC--
NanoViricides, Inc.